<DOC>
	<DOCNO>NCT00557323</DOCNO>
	<brief_summary>Patients enrol previous study ( SPD405-309 ) , expose lanthanum carbonate ( Fosrenol ) , eligible continue prescribe treatment hyperphosphatemia , include lanthanum carbonate ( Fosrenol ) , additional 5 year . Patients observe bone adverse event serious adverse event , well collection mortality data .</brief_summary>
	<brief_title>Long-term Effect Lanthanum Carbonate Bone</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Any patient exposure lanthanum carbonate SPD405309</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>